InstalabLoading...
InstalabLoading...
If you have asthma, hay fever, or eczema that flares in summer, after thunderstorms, or in damp environments, mold may be a hidden trigger that standard testing misses. Alternaria alternata is one of the most common outdoor molds in the world, and a blood test for IgE (immunoglobulin E, the antibody class your body produces during allergic reactions) shows whether your immune system has been primed to recognize it.
This test does not, on its own, prove you have a mold allergy. It tells you whether your body has built up the machinery for one. Used alongside your symptoms, it can explain unexplained asthma flares, flag who is at high risk for weather-related severe attacks, and help decide whether allergy shots are worth pursuing.
The test quantifies AA-IgE (Alternaria alternata-specific IgE) circulating in your blood. A positive result means your immune system has produced antibodies aimed at this mold. That state is called sensitization, and it sits one step short of a full allergy diagnosis. Sensitization plus exposure plus symptoms equals clinical allergy. You can be sensitized without ever feeling sick, and exposure determines whether the antibodies translate into wheeze, sneezing, or skin flares.
Sensitization is common. In a US laboratory series of 1.65 million patients, 16.6% tested positive for Alternaria-specific IgE, making it among the most frequent fungal sensitivities measured. In a Spanish allergy clinic population sensitized to fungi, 69.5% had antibodies to Alternaria or its main protein, Alt a 1.
Alternaria sensitization is an independent risk factor for childhood asthma. School-age children with positive Alternaria IgE are more likely to have asthma than children without it, though indoor allergens like dust mite tend to carry stronger weight in most US settings. Among urban children with asthma, even low-level positivity matters: an AA-IgE level of 0.10 kU/L or higher (a kilounit per liter, the standard unit for allergen antibodies) was linked to more frequent wheeze and higher exhaled nitric oxide, a marker of airway inflammation.
What this means for you: if your asthma flares without an obvious trigger, especially during late summer when outdoor mold spore counts peak, a positive Alternaria IgE points to a treatable cause that inhalers alone may not address.
The most striking link between Alternaria sensitization and a hard clinical event is thunderstorm asthma, where rain and wind rupture spores and pollens into respirable fragments that flood the lungs. In a UK study of seasonal asthmatics, 23 of 26 thunderstorm-asthma cases had Alternaria-specific IgE. Sensitization to Alternaria was a strong predictor of these epidemic attacks, with affected patients roughly 9 times more likely to test positive than controls.
If you have seasonal asthma and live in a region with active outdoor mold seasons, this single result can change how seriously you treat storm warnings.
In children with severe asthma, fungal sensitization (including Alternaria) marks a more difficult phenotype: earlier onset, higher total IgE, more reliance on oral steroids, and airway inflammation driven by IL-33 (interleukin-33, a signaling protein that resists ordinary steroid treatment). This is one reason a positive Alternaria IgE in a child with hard-to-control asthma is worth flagging to a specialist.
In adults, Alternaria-sensitized asthmatics tend to fall into the type 2-high group (a pattern of inflammation involving high IgE, eosinophils, and multiple allergic sensitizations) and are often candidates for biologic therapies that target this pathway.
Alternaria-specific IgE shows up more often in moderate-to-severe atopic dermatitis (eczema) than in milder cases. In a study of 100 atopic dermatitis patients tested with a multi-allergen molecular panel, IgE to Alt a 1 and Alt a 6 (a related Alternaria protein called enolase) was concentrated in those with severe skin disease and in patients who also had asthma or allergic rhinitis. Negative or class 0 results clustered in the moderate group.
If your eczema resists topical treatment, knowing whether mold sensitization is part of the picture can guide environmental and immunologic next steps.
Alternaria has a major allergen called Alt a 1, recognized by 80 to 98% of sensitized people. A positive whole-extract Alternaria IgE confirms sensitization, but adding component testing for Alt a 1 specifically increases diagnostic precision by separating true Alternaria allergy from cross-reactivity with related fungi. Both natural and recombinant Alt a 1 give reliable results comparable to whole-extract testing, and Alt a 1 is the protein used in the most rigorously studied immunotherapy trials.
These ranges come from published research using ImmunoCAP and similar fluoroenzyme assays for allergen-specific IgE in serum. They are research-supported orientation, not universal cutpoints. Different labs may use slightly different thresholds, and your symptoms and exposure history matter as much as the number itself.
| Range (kU/L) | Class | What It Suggests |
|---|---|---|
| Less than 0.10 | Negative | No detectable sensitization to Alternaria |
| 0.10 to 0.34 | Low-level sensitization | Detectable antibodies; in children with asthma, even this range tracks with more frequent wheeze |
| 0.35 to 16.8 | Clinically significant sensitization | Standard positive threshold; clinical relevance depends on symptoms and exposure |
| 16.8 or higher | High-level sensitization | 84% positive rate on bronchial provocation in one pediatric study, indicating high likelihood of true clinical allergy |
Compare your results within the same lab over time for the most meaningful trend. The biggest interpretive leap is from negative to positive; jumps within the positive range matter less than the pattern of your symptoms.
A single Alternaria IgE result is a snapshot. Sensitization can persist for years or decline naturally with age, and successful immunotherapy reliably lowers component-level IgE while raising protective IgG (a different antibody class that competes for the allergen). If you start allergen shots, retesting at 12 months and again at 24 to 36 months gives you objective evidence that the treatment is reshaping your immune response, not just masking symptoms.
If you are not on treatment but want to monitor a known sensitization, an annual measurement is reasonable, especially in children whose IgE profiles change with age. If you are starting a new intervention or changing environments, retest at 6 months to capture the trajectory.
A positive Alternaria IgE alongside relevant symptoms (wheeze, sneezing, itchy eyes during outdoor mold seasons, or stubborn eczema) is worth investigating with an allergist, especially if you have asthma. Useful next steps include component testing for Alt a 1 to confirm true Alternaria allergy, a broader aeroallergen panel to identify co-sensitizations, and Total IgE to gauge the overall atopic load. If you have severe or hard-to-control asthma, fungal sensitization can change the conversation around biologic therapy and should be reviewed by a specialist. For thunderstorm-asthma risk, a positive result is reason enough to have a written action plan and rescue medication ready during storm-season alerts.
If your result is negative but symptoms persist, do not stop the workup. Skin prick testing, nasal or bronchial provocation, and component-resolved diagnostics can each catch sensitization the standard blood test misses.
Evidence-backed interventions that affect your Alternaria Alternata Mold IgE level
Alternaria Alternata Mold IgE is best interpreted alongside these tests.